<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>Nusinersen_Renewal_Maintenance_Q1</name>
        <optionSourceResponseValue>false</optionSourceResponseValue>
        <questionText>Discontinuation Criteria:
Treatment should be discontinued if, prior to the fifth dose or every subsequent dose of
nusinersen if:
- there is no demonstrated achievement or maintenance of motor milestone function (as assessed
using age-appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment
initiation in patients who were pre-symptomatic at the time of treatment initiation; or
- there is no demonstrated maintenance of motor milestone function (as assessed using age-
appropriate scales: the HINE Section 2, CHOP INTEND, or HFMSE) since treatment initiation in
patients who were symptomatic at the time of treatment initiation; or
- permanent invasive ventilation is required.
*Permanent invasive ventilation is defined as the use of tracheostomy and a ventilator due to
progression of SMA that is not due to an identifiable and reversible cause*</questionText>
        <status>Active</status>
        <versionNumber>1</versionNumber>
    </assessmentQuestionVersion>
    <dataType>TextBlock</dataType>
    <developerName>Nusinersen_Renewal_Maintenance_Q1</developerName>
    <name>Nusinersen_Renewal_Maintenance_Q1</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
